Executive leadership at MEDICINOVA.
Board of directors at MEDICINOVA.
Research analysts covering MEDICINOVA.
Recent press releases and 8-K filings for MNOV.
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MNOV
New Projects/Investments
- MediciNova, Inc. has successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial.
- The trial is evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- This milestone is considered a significant step forward in the development of MN-166, allowing the company to move into the next phase of the trial.
- MN-166 is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, and is also in development for other neurodegenerative diseases such as progressive MS and DCM.
Aug 26, 2025, 11:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more